S& P 500 hits all time highs U.S.-Japan trade deal optimism
Today, Kamada Ltd . (NASDAQ:KMDA), a pharmaceutical company with a market capitalization of $382 million, informed shareholders about the withholding tax procedures for its special cash dividend, previously announced. The company, listed under the SIC code for Pharmaceutical (TADAWUL:2070) Preparations [2834], is following regulatory guidelines regarding the distribution of dividends to its shareholders. According to InvestingPro data, Kamada maintains strong financial health with a "GREAT" overall score, supported by robust liquidity metrics.
The announcement, made in a Form 6-K filing with the U.S. Securities and Exchange Commission, details the tax withholding process that will apply to the special dividend. This filing is incorporated by reference into Kamada’s Form S-8 Registration Statements, indicating its relevance to ongoing financial reporting. The company’s strong financial position is evidenced by its current ratio of 3.73, demonstrating ample liquidity to meet short-term obligations.
Kamada Ltd., based in Rehovot, Israel, is recognized for its work in the life sciences sector under the organization name 03 Life Sciences. The company’s business address is at 2 Holtzman St., Science Park, Rehovot, with the zip code 7670402, where it operates its principal executive offices.
The report was signed by Nir Livneh, Vice President General Counsel and Corporate Secretary of Kamada Ltd., ensuring compliance with the Securities Exchange Act of 1934. The exact withholding tax rates and procedures were not specified in the summary provided, but they are crucial for investors to understand their net dividend receipts.
Shareholders and interested parties can refer to the full text of the 6-K filing for a complete understanding of the tax implications associated with the special cash dividend. This information is based on a press release statement and is intended to provide clarity on the administrative aspects of the dividend process for Kamada Ltd.’s investors. With revenue growth of ~13% and trading slightly below its Fair Value, Kamada presents interesting potential for investors. Discover more detailed analysis and 6 additional key insights about KMDA with InvestingPro, including comprehensive valuation metrics and growth projections.
In other recent news, Kamada Ltd. reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.07, compared to the forecasted $0.05. However, the company’s revenue for the quarter was $39.01 million, slightly below the expected $40.11 million. Kamada also declared a special cash dividend of $0.20 per share, reflecting its strong financial position. The company forecasts significant growth in 2025, with a revenue target of $178-182 million. Kamada has opened a new plasma collection facility in San Antonio, Texas, which is expected to support an annual collection capacity of about 50,000 liters, contributing to its expansion strategy. Benchmark analysts initiated coverage on Kamada with a Buy rating and set a price target of $15.00, citing the company’s strategic growth initiatives and active research and development pipeline. H.C. Wainwright maintained a Buy rating on Kamada, with an $11.00 price target, highlighting the company’s strong performance and unique position in both plasma and biotechnology sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.